Observed Signal · Nov 5, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 2/5 · Sentiment: Positive
UK Sovereign AI Fund and Stripe CEO Back Potential Sciences
London-based startup Potential Sciences has raised a multi-million-dollar seed round backed by the UK government's Sovereign AI fund and Stripe CEO Patrick Collison. The company is developing AI infrastructure for scientific drug discovery, using AI, machine learning, and quantum chemistry simulations to model molecular behavior. Its physics-based AI approach aims to reduce the cost of chemical design calculations by up to 100 times. The Sovereign AI fund is also providing compute capacity. Other investors include Twin Path Ventures, Odyssey, Portfolio Ventures, Blue Wire Capital, rule30, Nauta Capital, and Lightfield Equity. The company declined to disclose the exact amount raised or its valuation. Potential Sciences was founded in November 2025 by Hatem Helal, a former Graphcore executive.
This funding round highlights growing investment in AI infrastructure for scientific research, which could have long-term implications for data and AI-driven advertising technologies, but it is not directly related to AdTech or MarTech.
Track Stripe Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Potential Sciences raised a multi-million-dollar seed round backed by UK Sovereign AI fund and Stripe CEO Patrick Collison.
- The Sovereign AI fund is also providing compute capacity to Potential Sciences.
- Potential Sciences uses AI, machine learning, and quantum chemistry simulations for drug discovery.
- The company's physics-based AI aims to make chemical design calculations 100 times cheaper.
- Potential Sciences was founded in November 2025 by Hatem Helal, a former Graphcore executive.
Connected Companies & Entities
2 Entities mapped“Stripe CEO Patrick Collison provided angel investment.”
“Investor in the seed round.”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
UK Sovereign AI Fund invests in security startup Augur
The UK government's £500M Sovereign AI Fund has invested in British security startup Augur, which uses AI to transform fragmented sensor networks into a real-time intelligence layer for national security and public safety. The fund also provides Augur access to Isambard-AI, the UK's most powerful AI supercomputer, for training large multi-camera datasets. Augur, whose founders include former Palantir executives, works with Transport for London and aims to improve security teams' ability to identify risks as they develop. The investment amount was not disclosed, but the fund typically invests between £5M and £10M in Seed and Series A rounds. This move underscores the UK government's commitment to building domestic AI capabilities for security.
Isomorphic Labs seeks $5B round at $50B valuation
Isomorphic Labs, Alphabet's AI drug discovery spinout led by Demis Hassabis, is reportedly in early-stage talks to raise approximately $5 billion at a valuation of around $50 billion, according to Bloomberg. This round would follow a $2.1 billion Series B in May and a $600 million round in 2025, bringing total raised to nearly $7.7 billion within 18 months. Despite the massive funding, the company has not yet tested any drug candidate in humans; clinical trials were initially planned for end of 2025, then delayed to late 2026. Investors are valuing the platform rather than a product, a record for a pre-clinical biotech. Revenue currently comes from partnerships with Eli Lilly, Novartis, and Johnson & Johnson, with milestone-based payments potentially reaching up to $2.9 billion. Skepticism remains, as Eli Lilly's CEO Dave Ricks has questioned the effectiveness of AI in drug discovery, noting that protein structure prediction is just one part of the challenge.
UK startup Pharosyn raises €2.5 million for pharma competitive intelligence platform
London-based Pharosyn, an AI-powered competitive intelligence platform for biopharma, has raised €2.5 million in a funding round led by Moonfire, with participation from Entrepreneurs First, Transpose Platform, and General Advance. The company plans to expand its platform and support wider adoption across pharmaceutical commercial and portfolio strategy teams. Founded in 2025 by Stephen Cowley and Joshua Hampson, Pharosyn monitors clinical, regulatory, and commercial data sources to produce strategic reports tailored to an organisation's pipeline. The funding is part of a broader trend of AI investment in pharma, with EU-Startups reporting approximately €75.3 million across seven comparable rounds this year.
Receive all future signals for Stripe & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.